The Bruton’s tyrosine kinase inhibitor, which is the first treatment to be specifically licensed for this form of blood cancer, is now available on the NHS in England as an additional option for patients whose cancer has not responded well to previous treatment.
Approximately 2,600 people are diagnosed every year in the UK with MZL, a group of slow-growing non-Hodgkin lymphomas that develop when there is uncontrollable growth in B cells…
